Abstracts

691 – Dolutegravir and Incident Diabetes Mellitus in West African People Living With HIV

Background Diabetes mellitus (DM) is a growing complication among people living with HIV (PLHIV), driven by traditional risk factors including age or obesity, as well as HIV-related factors such as exposure to certain antiretroviral therapy (ART). Dolutegravir (DTG), now the recommended first-line regimen in most settings, has been associated with metabolic disorders including weight gain,…

720 – Longitudinal Housing Instability and Frailty Incidence Among People With HIV in the United States

Background People with HIV (PWH) disproportionately experience both housing instability and frailty, an aging-related state of functional decline and vulnerability. While housing instability and frailty have been observed to commonly co-occur among PWH, it is critical to estimate how much of this association is related to housing instability preceding frailty. Methods We studied adult PWH engaged…

728 – Impact of TDF Discontinuation and Bisphosphonates on Bone Density T-Scores in People With HIV

Background People with HIV (PWH) have higher osteoporosis prevalence vs people without HIV. Bone loss is multifactorial and accelerated by chronic inflammation, ART, particularly TDF, and ageing. Bisphosphonates (BP) are recommended for osteoporosis treatment, but evidence on the extent to which TDF discontinuation and/or BP initiation improve bone health in PWH is limited. Methods In…

483 – Sex Differences in Cabotegravir Pharmacokinetics in the SEARCH Study in Kenya and Uganda

Background Long-acting cabotegravir (CAB-LA) is highly effective for HIV prevention. In Phase 2 trials, males had higher CAB pharmacokinetic (PK) trough concentrations than females after the first injection and lower troughs than females after subsequent injections. In the HIV treatment setting, in a large European cohort of LA CAB/rilpivirine after oral lead-in, CAB troughs were…

794 – Evaluating Broadly Neutralising Antibodies as Prevention for Paediatric HIV-1

Background HIV-specific broadly neutralising antibodies (bNAbs) have emerged as next generation paediatric interventions, with potential to prevent and treat HIV infection by neutralizing a wide spectrum of HIV-1 envelope (Env) glycoprotein variants. Neutralising breadth and potency against circulating strains can be enhanced by selecting appropriate bNAb combinations. Methods The LIFE study investigated preventive and therapeutic…

533 – Home CAB+RPV LA Support Sustained Persistence, Adherence & Viral Suppression in PWH With Challenges 

Background The Mobile Outreach Retention and Engagement (MORE) program at Whitman-Walker Health offers care navigation, transportation, and optional home injections for PWH initiating CAB+RPV LA with VL >200 copies/mL or no medical visit in < 6 months. MORE previously demonstrated promising 4-month outcomes; this analysis evaluates the durability of these results at 10 months (M10). Methods…

1027 – Feasibility and Acceptability of Cervico-Vaginal Self-Sampling for STI Testing in Nairobi Pharmacies

Background Sexually transmitted infections (STIs) remain a global public health challenge with the highest burden in low-resource settings where limited screening causes delayed diagnosis and continued transmission. The World Health Organization estimates over 1 million curable STIs occur daily.Human papillomavirus (HPV) is the most common, with high-risk types such as 16, 18, 31, 33, 45,…

294 – AAV-Delivered Antibody Reaches Mucosal Sites and Protects Against SHIV Infection in Rhesus Macaques

Background Long-term delivery of potent and broadly neutralizing antibodies (bNAbs) via adeno-associated virus (AAV) vectors offers a promising strategy for HIV prevention. Methods Four Indian-origin rhesus macaques received a one-time intramuscular administration of AAV9 encoding bNAb PCIN63, a CD4 binding site antibody with the hallmark VRC01-class features and similar neutralization breadth but with significantly less…

312 – HIV-1 Envelope x CD3 DART® Molecules Do Not Induce GALT Inflammatory Markers in Persons With HIV-1

Background MGD014 and MGD020 are bispecific DART® molecules that bind CD3 and bind HIV-1 Env with specificities derived from non-neutralizing mAbs A32 and 7B2, respectively. They redirect CD3+ T lymphocytes to kill HIV-1-infected, Env-expressing CD4+ T cells. When administered to HIV-1-infected humanized mice on ART, the combination of MGD020+MGD014 reduced cell-associated viral RNA in tissues…